Truist Securities Maintains Buy on Boston Scientific, Raises Price Target to $100
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Buy rating on Boston Scientific and raised its price target from $90 to $100, indicating confidence in the company's future performance.
October 14, 2024 | 1:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has reaffirmed its Buy rating on Boston Scientific and increased the price target to $100, suggesting a positive outlook for the company's stock.
The increase in the price target from $90 to $100 by Truist Securities, along with the maintained Buy rating, indicates a strong positive sentiment towards Boston Scientific's future performance. This is likely to have a positive impact on the stock price in the short term as investors may view this as a signal of confidence from a reputable analyst.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100